We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Interest in MicroRNA Research Driving Growth in Related Market Tools

By LabMedica International staff writers
Posted on 01 Jun 2012
A new study shows that an increased number of pharmaceutical and biotech companies are becoming interested in microRNA (miRNA) research due to advancements in molecular diagnostics and therapeutics. More...
As a result, a larger number of distribution companies are offering miRNA research tools and expanding the spectrum of their applications to cater to a wider range of life science areas.

In a recent study titled Analysis of MicroRNA Tools and Services Market in Europe, Frost & Sullivan (Palo Alto, CA, USA; www.frost.com), a global research and analysis company, examined various miRNA tools and services, including expression profiling and phenotypic screening, to determine that miRNA research is expanding across different fields.

The analysis found that miRNA research has become increasingly prominent in the cardiovascular, virology, endocrinology, plant science, and genetic disease fields. This has caused several other fields to develop an interest in auditing their gene expression analyses or epigenetic research by profiling miRNAs, explained Vinodh Jyotikumar, research consultant, Frost & Sullivan.

As new miRNAs and their functions are discovered, additional research fields may adopt an interest in the role of miRNAs in their disciplines, leading to the need for a wider variety of research tools.

A surge in miRNA research over the past four years has already led several life sciences vendors to offer miRNA research instruments. As competition intensifies, market participants will need to expand and differentiate their product options and capabilities to accommodate a broader range of interested fields.

"Service providers that do not offer in-house technologies must differentiate themselves by expanding tool options or adding capabilities," added Mr. Jyotikumar. "Companies may opt to provide multiple microarrays from various vendors, develop their own tools or offer specialized products, such as multiplex panels aimed at specific diseases."

Analysis of MicroRNA Tools and Services Market in Europe is part of the Frost & Sullivan Clinical Diagnostics Growth Partnership Services program.


Related Links:
Frost & Sullivan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.